Boston Scientific (NYSE:BSX) Stock Price Target Cut by Leerink Partners

Boston Scientific (NYSE:BSX) had its target price cut by equities researchers at Leerink Partners from $60.00 to $55.00 in a report issued on Friday. Leerink Partners’ price objective suggests a potential upside of 27.40% from the stock’s previous close.

BSX has been the subject of several other research reports. Piper Sandler reissued an “overweight” rating and issued a $65.00 price objective (down from $90.00) on shares of Boston Scientific in a research report on Friday, June 12th. Wall Street Zen cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Sunday, August 2nd. Wells Fargo & Company lowered their price target on Boston Scientific from $50.00 to $48.00 and set an “equal weight” rating for the company in a report on Wednesday, September 23rd. Oppenheimer cut their price objective on Boston Scientific from $85.00 to $65.00 and set an “outperform” rating on the stock in a research report on Monday, September 21st. Finally, Needham & Company LLC cut their price objective on Boston Scientific from $77.00 to $57.00 and set a “buy” rating on the stock in a research report on Wednesday, July 8th. One analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $68.60.

Boston Scientific Trading Up 1.0%

Shares of NYSE:BSX traded up $0.44 during trading on Friday, reaching $43.17. 1,893,435 shares of the stock were exchanged, compared to its average volume of 18,608,648. The firm’s 50-day moving average price is $46.56 and its 200 day moving average price is $50.52. The firm has a market cap of $62.56 billion, a price-to-earnings ratio of 17.48, a price-to-earnings-growth ratio of 1.03 and a beta of 0.58. Boston Scientific has a 12-month low of $41.38 and a 12-month high of $105.65. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating the consensus estimate of $0.83 by $0.03. The firm had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. Boston Scientific’s revenue for the quarter was up 7.5% compared to the same quarter last year. During the same quarter last year, the firm posted $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, sell-side analysts anticipate that Boston Scientific will post 3.25 earnings per share for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, Director David Habiger bought 2,100 shares of Boston Scientific stock in a transaction dated Wednesday, August 5th. The stock was bought at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the purchase, the director owned 17,160 shares in the company, valued at $816,644.40. This represents a 13.94% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Michael Mahoney bought 186,240 shares of Boston Scientific stock in a transaction dated Monday, August 3rd. The shares were acquired at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the purchase, the chief executive officer owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. The trade was a 13.27% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired a total of 194,522 shares of company stock valued at $9,385,210 in the last three months. Corporate insiders own 0.34% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. South Plains Financial Inc. acquired a new stake in shares of Boston Scientific in the fourth quarter valued at approximately $39,000. Clal Insurance Enterprises Holdings Ltd bought a new stake in shares of Boston Scientific during the first quarter valued at approximately $28,000. Cassaday & Co Wealth Management LLC acquired a new position in shares of Boston Scientific during the first quarter worth approximately $32,000. Measured Wealth Private Client Group LLC boosted its position in shares of Boston Scientific by 244.9% during the first quarter. Measured Wealth Private Client Group LLC now owns 545 shares of the medical equipment provider’s stock worth $34,000 after buying an additional 387 shares during the period. Finally, Kelleher Financial Advisors bought a new position in Boston Scientific in the 2nd quarter worth approximately $25,000. 89.07% of the stock is currently owned by institutional investors.

About Boston Scientific

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company’s portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.